NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $8.50.

Several equities analysts have weighed in on NRSN shares. Roth Mkm assumed coverage on NeuroSense Therapeutics in a research note on Tuesday, March 10th. They set a “buy” rating and a $3.00 price objective on the stock. Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th.

NeuroSense Therapeutics Trading Up 7.8%

Shares of NASDAQ:NRSN opened at $0.81 on Wednesday. The stock’s fifty day simple moving average is $0.79 and its two-hundred day simple moving average is $0.93. NeuroSense Therapeutics has a 1-year low of $0.63 and a 1-year high of $2.60. The stock has a market cap of $26.34 million, a PE ratio of -1.50 and a beta of 1.70.

Institutional Trading of NeuroSense Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics during the fourth quarter worth $77,000. Two Sigma Investments LP bought a new stake in NeuroSense Therapeutics during the third quarter worth $26,000. Squarepoint Ops LLC lifted its holdings in NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the period. Finally, Jane Street Group LLC bought a new stake in NeuroSense Therapeutics during the second quarter worth $54,000. 1.04% of the stock is currently owned by institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.